DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Cardiovascular Diabetology

JUNE 14, 2024

Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.

Kidney Disease 52

Kidney Disease Heart Failure Diabetes Risk Factors 52

DAIC

JUNE 21, 2024

announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our

Heart Failure 105

Heart Failure Preserved Ejection Fraction Diabetes Research 105

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

DAIC

AUGUST 21, 2024

21, 2024 — The incidence rate of heart failure was 2- to 3-fold higher among American Indian populations than rates observed in studies focused on other population groups, such as African American, Hispanic or white adults, in a new study published in the Journal of the American Heart Association.

Heart Failure 52

Heart Failure Risk Factors Heart Attack Heart attacks 52

HCPLive

JUNE 18, 2024

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

Heart Failure 69

Heart Failure Diabetes Research 69

DAIC

APRIL 30, 2024

Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 96

Preserved Ejection Fraction Diabetes Heart Failure Obesity 96

Cardiovascular Diabetology

APRIL 28, 2024

Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.

Heart Failure 52

Heart Failure Diabetes Biomarkers Outcomes 52

Cardiovascular Diabetology

AUGUST 6, 2024

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.

Coronary Artery Disease 98

Coronary Artery Disease Diabetes Myocardial Infarction Heart Failure 98

Cardiovascular Diabetology

JUNE 6, 2024

Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outc.

Diabetes 64

Diabetes Heart Failure Outcomes Research 64

HeartRhythm

APRIL 30, 2024

We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.

Heart Failure 40

Heart Failure Obesity Diabetes Outcomes 40

Medical Xpress - Cardiology

DECEMBER 30, 2023

For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27 in eClinicalMedicine.

Heart Failure 75

Heart Failure Diabetes 75

American College of Cardiology

JULY 12, 2024

What are the racial and ethnic differences among individuals with diabetic dilated cardiomyopathy at high risk for overt heart failure?

Cardiomyopathy 56

Cardiomyopathy Diabetes Heart Failure Article 56

The British Journal of Cardiology

AUGUST 6, 2024

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heart failure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.

Inpatient 52

Inpatient Heart Failure Diabetes Hospital 52

Science Daily - Heart Disease

JULY 24, 2024

In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy.

Preserved Ejection Fraction 107

Preserved Ejection Fraction Diabetes Heart Failure 107

American College of Cardiology

JULY 2, 2024

What is the effect of AT-001, an aldose reductase inhibitor, on exercise capacity among individuals with diabetic cardiomyopathy (DbCM) with reduced exercise capacity and at high risk for progression to overt heart failure (HF)?

Cardiomyopathy 53

Cardiomyopathy Diabetes Exercise Heart Failure 53

Cardiovascular Diabetology

JANUARY 19, 2024

Diabetes mellitus (DM) is associated with a worse prognosis in patients with heart failure. Our aim was to analyze the clinical and imaging features of patients with DM and their association with outcomes in c.

Diabetes 95

Diabetes Outcomes Heart Failure Cardiomyopathy 95

Cardiovascular Diabetology

JANUARY 8, 2024

Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Myocardial Infarction Kidney Disease Diabetes 105

Frontiers in Cardiovascular Medicine

DECEMBER 17, 2023

These conditions have an increasing share in the health burden worldwide due to worsening endemic of hypertension, obesity, and diabetes. However, the same set of genes were significantly induced in the Trp53inp2-cKO hearts under both mechanical and metabolic stresses.

Heart Failure 64

Heart Failure Diet Obesity Diabetes 64

Circulation

FEBRUARY 12, 2024

BACKGROUND:Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. years, type 2 diabetes duration of 4.0±2.7 0.86];P=0.022).

Diabetes 80

Diabetes Outcomes Myocardial Infarction Heart Failure 80

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 8, 2024

Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. Accounting for all-cause mortality, we obtained the incidence for heart failure hospitalization at 5 years follow-up; overall and in each SDI group. and 0.80, respectively). and 0.80, respectively).

Heart Failure 40

Heart Failure Diabetes Outpatient Hospital 40

Cardiovascular Diabetology

JULY 9, 2024

To adapt risk prediction equations for myocardial infarction (MI), stroke, and heart failure (HF) among patients with type 2 diabetes in real-world settings using cross-institutional electronic health records.

Myocardial Infarction 52

Myocardial Infarction Diabetes Heart Failure Outcomes 52

Hypertension Journal

NOVEMBER 22, 2023

BACKGROUND:Diabetes is an important risk factor for heart failure (HF) and is associated with left ventricular (LV) diastolic dysfunction. However, diabetic comorbid conditions, such as nocturnal hypertension, as predictors of diastolic dysfunction are not known in the absence of an HF period. Hypertension, Ahead of Print.

Hypertension 40

Hypertension Heart Failure Diabetes Risk Factors 40

DAIC

MARCH 5, 2024

Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heart failure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.

Heart Failure 52

Heart Failure Innovation Hospital Technology 52

Cardiovascular Diabetology

AUGUST 11, 2024

We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.

Blood Pressure 111

Blood Pressure Heart Failure Hypertension Diabetes 111

European Journal of Heart Failure

SEPTEMBER 26, 2023

Abstract Diagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. Use of this acronym would enable the early diagnosis of heart failure.

Heart Failure 40

Heart Failure Coronary Artery Disease Outpatient Document 40

Hypertension Journal

FEBRUARY 22, 2024

years for women with type 2 diabetes. 1.29) for women with type 2 diabetes.CONCLUSIONS:In women with diabetes, a history of hypertensive disorders of pregnancy was associated with an increased risk of incident cardiovascular disease and should be considered as a risk enhancer. years for women with type 1 and 29.8

Cardiovascular Disease 74

Cardiovascular Disease Hypertension Diabetes Myocardial Infarction 74

Heart BMJ

DECEMBER 15, 2023

Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. Strain values are absolute.

Heart Failure 45

Heart Failure Outpatient Tricuspid Cardiomyopathy 45

Open Heart

NOVEMBER 27, 2023

Introduction This study aimed to evaluate the use and dose of loop diuretics (LDs) across the entire ejection fraction (EF) spectrum in a large, ‘real-world’ cohort of chronic heart failure (HF) patients. Data regarding daily diuretic dose were stratified by furosemide dose equivalent (FDE)>80 mg or ≤80 mg.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Outpatient Diabetes 52

Cardiovascular Diabetology

MARCH 5, 2024

Atrial fibrillation (AF) has been linked to an increased risk of cardiovascular death, overall mortality and heart failure in patients with type 2 diabetes mellitus (T2DM). The present study investigated the a.

Atrial Fibrillation 59

Atrial Fibrillation Diabetes Heart Failure Research 59

HeartRhythm

JUNE 4, 2024

Diabetes mellitus (DM) confers an increased risk of sudden cardiac death (SCD) independent of its associated cardiovascular comorbidities. Diabetes mellitus induces adverse structural, electrophysiological, and autonomic cardiac remodeling which can increase one’s risk of ventricular arrhythmias and SCD.

Sudden Cardiac Death 40

Sudden Cardiac Death Arrhythmia Diabetes Electrophysiology 40

Open Heart

MAY 23, 2024

Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia. This study examines whether pregestational heart failure increases the risk of pre-eclampsia.

Heart Disease 98

Heart Disease Heart Failure Risk Factors Obesity 98

Circulation

NOVEMBER 10, 2023

Background:The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD).Methods:Adults Circulation, Ahead of Print.

Cardiovascular Disease 40

Cardiovascular Disease Heart Failure Diabetes Cardiomyopathy 40

Circulation: Heart Failure

MARCH 8, 2024

Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White.

Heart Failure 40

Heart Failure Atherosclerosis Kidney Disease Risk Factors 40

Cardiovascular Diabetology

JANUARY 31, 2024

Diabetic cardiomyopathy (DbCM) is a form of Stage B heart failure (HF) at high risk for progression to overt disease. Using baseline characteristics of study participants from the Aldose Reductase Inhibition f.

Cardiomyopathy 40

Cardiomyopathy Diabetes Heart Failure Research 40

The American Journal of Cardiology

JULY 25, 2024

Publication date: Available online 25 July 2024 Source: The American Journal of Cardiology Author(s): Chintal H. Shah, Gregg C. Fonarow, Justin B. Echouffo-Tcheugui

Heart Failure 40

Heart Failure Diabetes 40